Those fighting non-Hodgkin's lymphoma will have another possible treatment. The U.S. government has approved the sale of chemotherapy drug Treanda.

Reuters Health reported that drug company Cephalon Inc. announced last week the approval to sell the drug, which was previously approved in March by the U.S. Food and Drug Administration.  

Cephalon reported one trial of Treanda showed that the drug delayed progression of the disease for more than 9 months. Treanda is used in chronic lymphocytic leukemia, a prevalent form of leukemia in the United States.

An estimated 30,000 people in the United States will be diagnosed with the disease this year, according to Reuters.